252 related articles for article (PubMed ID: 8981185)
1. In vitro susceptibility of Trichosporon beigelii to antifungal agents.
Perparim K; Nagai H; Hashimoto A; Goto Y; Tashiro T; Nasu M
J Chemother; 1996 Dec; 8(6):445-8. PubMed ID: 8981185
[TBL] [Abstract][Full Text] [Related]
2. [Multisite evaluation of a colorimetric broth microdilution antifungal susceptibility testing].
Yamane N; Igari J
Rinsho Byori; 1997 Feb; 45(2):190-9. PubMed ID: 9121005
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice.
Kamberi P; Atsuro H; Takayoshi T; Masaru N
Chemotherapy; 1998; 44(1):55-62. PubMed ID: 9444410
[TBL] [Abstract][Full Text] [Related]
4. Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates.
Arikan S; Hasçelik G
Diagn Microbiol Infect Dis; 2002 Jun; 43(2):107-11. PubMed ID: 12088616
[TBL] [Abstract][Full Text] [Related]
5. [Antifungal susceptibility of clinically isolated Candida albicans by broth microdilution method].
Yamazumi T; Kuroda T; Ohata T; Obana Y; Furuta I
Kansenshogaku Zasshi; 1998 Aug; 72(8):813-9. PubMed ID: 9780584
[TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal activity of the new triazole D0870 against Penicillium marneffei compared with that of amphotericin B, fluconazole, itraconazole, miconazole and flucytosine.
Boon-Long J; Mekha N; Poonwan N; Kusum M; Mikami Y; Yazawa K; Konyama K
Mycoses; 1996; 39(11-12):453-6. PubMed ID: 9145003
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the microdilution, Etest and disk diffusion methods for antifungal susceptibility testing of clinical strains of Trichosporon spp.
Metin DY; Hilmioglu-Polat S; Hakim F; Inci R; Tumbay E
J Chemother; 2005 Aug; 17(4):404-8. PubMed ID: 16167520
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.
Hazirolan G; Canton E; Sahin S; Arikan-Akdagli S
Antimicrob Agents Chemother; 2013 Oct; 57(10):4841-7. PubMed ID: 23877683
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
10. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
Abdel-Salam HA
Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility of yeasts for fluconazole and itraconazole. Evaluation of a microdilution test.
Nenoff P; Oswald U; Haustein UF
Mycoses; 1999; 42(11-12):629-39. PubMed ID: 10680439
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
15. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.
Te Dorsthorst DT; Mouton JW; van den Beukel CJ; van der Lee HA; Meis JF; Verweij PE
Antimicrob Agents Chemother; 2004 Aug; 48(8):3147-50. PubMed ID: 15273136
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of amphotericin B, flucytosine and fluconazole against yeasts causing bloodstream infections.
Berenguer J; Fernández-Baca V; Sánchez R; Bouza E
Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):362-5. PubMed ID: 7649205
[TBL] [Abstract][Full Text] [Related]
17. The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Mariné M; Bom VL; de Castro PA; Winkelstroter LK; Ramalho LN; Brown NA; Goldman GH
Virulence; 2015; 6(5):476-86. PubMed ID: 25751127
[TBL] [Abstract][Full Text] [Related]
18. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal susceptibilities of Trichosporon species.
Paphitou NI; Ostrosky-Zeichner L; Paetznick VL; Rodriguez JR; Chen E; Rex JH
Antimicrob Agents Chemother; 2002 Apr; 46(4):1144-6. PubMed ID: 11897610
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method.
Pfaller MA; Barry AL
Mycopathologia; 1995; 130(1):3-9. PubMed ID: 7666925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
